Cancer Chemotherapy Associated Nausea and Vomiting (CINV) refers to nausea and vomiting that may occur after a patient with cancer receives chemotherapy. CINV therapeutics aim to prevent and manage nausea and vomiting among cancer patients undergoing chemotherapy. The two main types of drugs used for CINV treatment are 5-HT3 receptor antagonists that block serotonin receptors in the body and NK1 receptor antagonists that block substance P. These drugs play a key role in preventing nausea and vomiting and improving quality of life for cancer patients.
The global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market is estimated to be valued at US$ 3537.91 Mn in 2024 and is expected to exhibit a CAGR of 5.3% over the forecast period 2024-2031, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
The growing number of chemotherapy treatment cases is expected to drive the demand for CINV therapeutics over the forecast period. According to the International Agency for Research on Cancer (IARC), the number of new cancer cases around the world is expected to rise by over 70% by 2040. Chemotherapy is one of the most widely used treatment options for various types of cancers. The increase in cancer incidence rate directly translates to rising chemotherapy administration which subsequently increases the risk of CINV. This growing prevalence of cancer and increasing preference for chemotherapy offers significant opportunity for manufacturers of CINV therapeutics to expand their product portfolio and tap into this growing patient pool. Continuous development of more efficacious drugs with better side effect profile will also be important to meet the needs of increasing number of chemotheraphy patients at risk of CINV.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate as the Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics market requires high R&D investment and strict regulatory approvals. However, generics competition post patent expiry of major drugs poses threat.
Bargaining power of buyers: The bargaining power of buyers is high given the price sensitivity of patients and availability of substitutes. Buyers can negotiate for lower prices and switch between brands easily.
Bargaining power of suppliers: The bargaining power of suppliers is moderate as key active pharmaceutical ingredients have few substitutes and suppliers have established relations with pharma companies.
Threat of new substitutes: The threat of new substitutes is high as continual R&D leads to development of novel therapeutics and alternative treatment modalities to manage cancer chemotherapy associated nausea and vomiting.
Competitive rivalry: Competition in the market is high due to presence of global as well as local players.
SWOT Analysis
Strength: Wide product portfolio and strong pipeline of pharmaceutical companies. Increasing incidence of cancer and advancements in chemotherapy drive market growth.
Weakness: High R&D costs, stringent regulations and patent cliffs. Side effects associated with drugs lower compliance.
Opportunity: Emerging economies with growing healthcare infrastructure and expenditure present opportunities for market players. Combination therapies widen treatment options.
Threats: Threat from generic competition post patent expiry. Social stigma associated with cancer in developing regions.
Key Takeaways
The global Cancer Chemotherapy Associated Nausea And Vomiting Therapeutics Market Size is expected to witness high growth. Rising cancer prevalence worldwide backed by increasing use of highly emetogenic chemotherapy regimens escalates demand for anti-emetic drugs. As per WHO, cancer burden is projected to increase to 27.5 million new cases and 16.3 million cancer deaths by 2040. The global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market is estimated to be valued at US$ 3537.91 Mn in 2024 and is expected to exhibit a CAGR of 5.3% over the forecast period 2024-2031.
Regional analysis: North America dominates the global market and is expected to maintain its lead over the forecast period. Favorable reimbursement policies coupled with growing focus on innovative treatment options fuels market growth in the region. However, Asia Pacific is anticipated to witness the fastest growth over the next few years. Improving access to healthcare in major Asian countries and rise in medical tourism in India and Southeast Asia support market expansion.
Key players operating in the Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics market are Nature Essential Foods Pvt Ltd, Lotus Bakeries, General Mills Inc., Clif Bar & Company, ProBar LLC, Post Holdings Inc., BumbleBar Inc., PepsiCo Inc., Eat Anytime, TORQ Limited, OTE Sports Ltd, Kind LLC, Science in Sports PLC, and Kellogg Company.
Explore more related article on this topic: https://www.newsanalyticspro.com/cancer-chemotherapy-associated-nausea-and-vomiting-therapeutics-market/
